Government of India has brought 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 per cent, which would reduce their retail prices by up to 85 per cent. The National Pharmaceutical Pricing Authority (NPPA) order will affect the MRP for 105 brands will be reduced up to 85 per cent entailing minimum saving of Rs 105 crore to consumers.
Currently, 57 anti-cancer drugs are under price control as scheduled formulations. Now 42 non-scheduled anti-cancer medicines have been selected for price regulation by restricting trade margin on the selling price (MRP) up to 30 per cent.
As more data is being collected from hospitals and manufacturers to finalize the list, the drug manufacturers have been given seven days to recalculate the prices and inform the NPPA, state drug controllers, stockiest and retailers.
The revised prices shall come into effect from March, 8, 2019.